Abstract
More than 300 million people worldwide have diabetes. It is estimated that by the year 2035, the number of people affected by this disease will rise to 592 million. Peroxisome proliferator-activated receptor gamma (PPARγ) agonists such as thiazolidinediones (TZDs) have been proven to effectively reduce the risk of developing type II diabetes and the insulin resistance present when the disease is manifested. However, TZDs have several adverse effects that restrict their potential use. Recent evidence suggests that the classical transactivation activity of PPARγ could be responsible for the adverse effects of PPARγ agonists. Moreover, the inhibition of the CDK5-mediated phosphorylation of PPARγ at Ser273 is a key determinant of the antidiabetic effects of PPARγ agonists. Functional foods could serve as a new mode of preventing and managing type II diabetes. In this chapter, we review the evidence needed to demonstrate the beneficial effects and the absence of adverse effects of the PPARγ-targeted compounds both in vitro and in vivo. We also review the natural products and plant extracts that have been described to bind PPARγ and how these compounds can be discovered through virtual screening (VS) procedures. More research about the molecular mechanisms and the efficacy of PPARγ-mediated antidiabetic compounds is needed prior to developing functional foods for the prevention of diabetes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
International Diabetes Federation (2013) IDF Diabetes Atlas, 6th edn. http://www.idf.org/diabetesatlas
Roglic G, Unwin N, Bennett PH et al (2005) The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28:2130–2135
World Health Organization (2013) Diabetes. Fact sheet N. 312. http://www.who.int/mediacentre/factsheets/fs312/en/
Khavandi K, Amer H, Ibrahim B, Brownrigg J (2013) Strategies for preventing type 2 diabetes: an update for clinicians. Ther Adv Chronic Dis 4:242–261. doi:10.1177/2040622313494986
Shaw JE, Zimmet PZ, de Courten M et al (1999) Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care 22:399–402
Rudkowska I (2009) Functional foods for health: focus on diabetes. Maturitas 62:263–269. doi:10.1016/j.maturitas.2009.01.011
Perera P, Li Y (2011) Mushrooms as a functional food mediator in preventing and ameliorating diabetes. Funct Foods Health Dis 4:161–171
Ballali S, Lanciai F (2012) Functional food and diabetes: a natural way in diabetes prevention? Int J Food Sci Nutr 63 Suppl 1:51–61. doi:10.3109/09637486.2011.637487
Garcia-Vallvé S, Palau J (1998) Nuclear receptors, nuclear-receptor factors, and nuclear-receptor-like orphans form a large paralog cluster in Homo sapiens. Mol Biol Evol 15:665–682
Buchanan TA, Xiang AH, Peters RK et al (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796–2803
Knowler WC, Hamman RF, Edelstein SL et al (2005) Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150–1156
Gerstein HC, Yusuf S, Bosch J et al (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096–1105. doi:10.1016/S0140-6736(06)69420-8
DeFronzo RA, Abdul-Ghani MA (2011) Preservation of β-cell function: the key to diabetes prevention. J Clin Endocrinol Metab 96:2354–2366. doi:10.1210/jc.2011-0246
Song MK, Roufogalis BD, Huang THW (2012) Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology. Br J Pharmacol 165:4–19. doi:10.1111/j.1476-5381.2011.01411.x
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471. doi:10.1056/NEJMoa072761
Lewis JD, Ferrara A, Peng T et al (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34:916–922. doi:10.2337/dc10-1068
Feldman PL, Lambert MH, Henke BR (2008) PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr Top Med Chem 8:728–749
Amato AA, Rocha Neves F de A (2012) Idealized PPARγ-based therapies: lessons from bench and bedside. PPAR Res 2012:978687. doi:10.1155/2012/978687
Bortolini M, Wright MB, Bopst M, Balas B (2013) Examining the safety of PPAR agonists—current trends and future prospects. Expert Opin Drug Saf 12:65–79. doi:10.1517/14740338.2013.741585
Turner LW, Nartey D, Stafford RS et al (2014) Ambulatory treatment of Type 2 diabetes mellitus in the United States, 1997–2012. Diabetes Care 37:985–992. doi:10.2337/dc13-2097
Gelman L, Feige JN, Desvergne B (2007) Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochim Biophys Acta 1771:1094–1107. doi:10.1016/j.bbalip.2007.03.004
Bruning JB, Chalmers MJ, Prasad S et al (2007) Partial agonists activate PPARgamma using a helix 12 independent mechanism. Structure 15:1258–1271. doi:10.1016/j.str.2007.07.014
Pochetti G, Godio C, Mitro N et al (2007) Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands. J Biol Chem 282:17314–17324. doi:10.1074/jbc.M702316200
Farce A, Renault N, Chavatte P (2009) Structural insight into PPARgamma ligands binding. Curr Med Chem 16:1768–1789
Guasch L, Sala E, Valls C et al (2011) Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity. J Comput Aided Mol Des 2011:717–728. doi:10.1007/s10822-011-9446-9
Choi JH, Banks AS, Estall JL et al (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466:451–456. doi:10.1038/nature09291
Choi JH, Banks AS, Kamenecka TM et al (2011) Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477:477–481. doi:10.1038/nature10383
Vázquez M, Silvestre JS, Prous JR (2002) Experimental approaches to study PPAR gamma agonists as antidiabetic drugs. Methods Find Exp Clin Pharmacol 24:515–523
Merk D, Steinhilber D, Schubert-Zsilavecz M (2014) Characterizing ligands for farnesoid X receptor-available in vitro test systems for farnesoid X receptor modulator development. Expert Opin Drug Discov 9:27–37
Guasch L, Sala E, Castell-Auví A et al (2012) Identification of PPARgamma partial agonists of natural origin (I): development of a virtual screening procedure and in vitro validation. PLoS One 7:e50816. doi:10.1371/journal.pone.0050816
Simmonds MSJ, Howes M-JR (2005) Plants used in the treatment of diabetes. In: Soumyanath A (ed) Traditional medicines for Modern Times. Antidiabetic plants. Taylor & Francis Group, Abingdon, pp 19–82
Bnouham M, Ziyyat A, Mekhfi H et al (2006) Medicinal plants with potential antidiabetic activity-A review of ten years of herbal medicine research (1990–2000). Int J Diabetes Metab 14:1–25
Hong J (2011) Role of natural product diversity in chemical biology. Curr Opin Chem Biol 15:350–354. doi:10.1016/j.cbpa.2011.03.004
Huang TH-W, Kota BP, Razmovski V, Roufogalis BD (2005) Herbal or natural medicines as modulators of peroxisome proliferator-activated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin Pharmacol Toxicol 96:3–14. doi:10.1111/j.1742-7843.2005.pto960102.x
Rau O, Wurglics M, Dingermann T et al (2006) Screening of herbal extracts for activation of the human peroxisome proliferator-activated receptor. Pharmazie 61:952–956
Jacob A, Wu R, Zhou M, Wang P (2007) Mechanism of the anti-inflammatory effect of curcumin: PPAR-gamma activation. PPAR Res 2007:89369. doi:10.1155/2007/89369
Huang TH-W, Teoh AW, Lin B-L et al (2009) The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol Res 60:195–206. doi:10.1016/j.phrs.2009.03.020
Mueller M, Jungbauer A (2009) Culinary plants, herbs and spices—a rich source of PPARγ ligands. Food Chem 117:660–667. doi:10.1016/j.foodchem.2009.04.063
Christensen KB, Minet A, Svenstrup H et al (2009) Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake. Phytother Res 23:1316–1325. doi:10.1002/ptr.2782
Christensen KB, Jørgensen M, Kotowska D et al (2010) Activation of the nuclear receptor PPARγ by metabolites isolated from sage (Salvia officinalis L.). J Ethnopharmacol 132:127–133. doi:10.1016/j.jep.2010.07.054
Christensen KB, Petersen RK, Kristiansen K, Christensen LP (2010) Identification of bioactive compounds from flowers of black elder (Sambucus nigra L.) that activate the human peroxisome proliferator-activated receptor (PPAR) gamma. Phytother Res 24 (Suppl 2):S129–132. doi:10.1002/ptr.3005
Jungbauer A, Medjakovic S (2012) Anti-inflammatory properties of culinary herbs and spices that ameliorate the effects of metabolic syndrome. Maturitas 71:227–239. doi:10.1016/j.maturitas.2011.12.009
Rozema E, Atanasov AG, Fakhrudin N et al (2012) Selected extracts of Chinese herbal medicines: their effect on NF-κB, PPARα and PPARγ and the respective bioactive compounds. Evid Based Complement Alternat Med 2012:983023. doi:10.1155/2012/983023
Ortuño Sahagún D, Márquez-Aguirre AL, Quintero-Fabián S et al (2012) Modulation of PPAR-γ by Nutraceutics as complementary treatment for obesity-related disorders and inflammatory diseases. PPAR Res 2012:318613. doi:10.1155/2012/318613
Yang MH, Avula B, Smillie T et al (2013) Screening of medicinal plants for PPARα and PPARγ activation and evaluation of their effects on glucose uptake and 3T3-L1 adipogenesis. Planta Med 79:1084–1095. doi:10.1055/s-0033-1350620
Weidner C, Wowro SJ, Rousseau M et al (2013) Antidiabetic effects of chamomile flowers extract in obese mice through transcriptional stimulation of nutrient sensors of the peroxisome proliferator-activated receptor (PPAR) Family. PLoS One 8:e80335. doi:10.1371/journal.pone.0080335
Puhl AC, Bernardes A, Silveira RL et al (2012) Mode of peroxisome proliferator-activated receptor γ activation by luteolin. Mol Pharmacol 81:788–799. doi:10.1124/mol.111.076216
Weidner C, de Groot JC, Prasad A et al (2012) Amorfrutins are potent antidiabetic dietary natural products. Proc Natl Acad Sci U S A 109:7257–7262. doi:10.1073/pnas.1116971109
Wu G, Yi J, Liu L et al (2013) Pseudoginsenoside F11, a novel partial PPAR γ agonist, promotes adiponectin oligomerization and secretion in 3T3-L1 adipocytes. PPAR Res 2013:701017. doi:10.1155/2013/701017
Hwang J-T, Kim S-H, Lee M-S et al (2007) Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. Biochem Biophys Res Commun 364:1002–1008. doi:10.1016/j.bbrc.2007.10.125
Hwang J-T, Lee M-S, Kim H-J et al (2009) Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways. Phytother Res 23:262–266. doi:10.1002/ptr.2606
Gong Z, Huang C, Sheng X et al (2009) The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology 150:104–113. doi:10.1210/en.2008-0322
Lee H-M, Lee O-H, Lee B-Y (2010) Effect of Ginsenoside Rg3 and Rh2 on Glucose uptake in insulin-resistant muscle cells. J Korean Soc Appl Biol Chem 53:106–109. doi:10.3839/jksabc.2010.018
Yoshikawa M, Matsuda H (2005) Traditional Chinese and Kampo medicines. In: Soumyanath A (ed) Traditional medicines for Modern Times. Antidiabetic plants. Taylor & Francis Group, Abingdon, pp 135–149
Kuroda M, Mimaki Y, Sashida Y et al (2003) Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-A(y) mice. Bioorg Med Chem Lett 13:4267–4272
Nakagawa K, Kishida H, Arai N et al (2004) Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-A(y) mice. Biol Pharm Bull 27:1775–1778
Kuroda M, Mimaki Y, Honda S et al (2010) Phenolics from Glycyrrhiza glabra roots and their PPAR-gamma ligand-binding activity. Bioorg Med Chem 18:962–970. doi:10.1016/j.bmc.2009.11.027
Salam NK, Huang TH-W, Kota BP et al (2008) Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem Biol Drug Des 71:57–70. doi:10.1111/j.1747-0285.2007.00606.x
Zarzuelo A, Jiménez I, Gámez MJ et al (1996) Effects of luteolin 5-O-beta-rutinoside in streptozotocin-induced diabetic rats. Life Sci 58:2311–2316
De Groot JC, Weidner C, Krausze J et al (2013) Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor γ. J Med Chem 56:1535–1543. doi:10.1021/jm3013272
Atanasov AG, Wang JN, Gu SP et al (2013) Honokiol: a non-adipogenic PPARγ agonist from nature. Biochim Biophys Acta 1830:4813–4819. doi:10.1016/j.bbagen.2013.06.021
Cichewicz RH, Clifford LJ (2005) Native American medicine. In: Soumyanath A (ed) Traditional medicines for Modern Times. Antidiabetic plants. Taylor & Francis Group, Abingdon, pp 169–177
Leach MJ, Kumar S (2012) Cinnamon for diabetes mellitus. Cochrane database Syst Rev 9:CD007170. doi:10.1002/14651858.CD007170.pub2
Weisberg SP, Leibel R, Tortoriello D V (2008) Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology 149:3549–3558. doi:10.1210/en.2008-0262
Rinwa P, Kaur B, Jaggi AS, Singh N (2010) Involvement of PPAR-gamma in curcumin-mediated beneficial effects in experimental dementia. Naunyn Schmiedebergs Arch Pharmacol 381:529–539. doi:10.1007/s00210-010-0511-z
Wang H-M, Zhao Y-X, Zhang S et al (2010) PPARgamma agonist curcumin reduces the amyloid-beta-stimulated inflammatory responses in primary astrocytes. J Alzheimers Dis 20:1189–1199. doi:10.3233/JAD-2010-091336
Narala VR, Smith MR, Adapala RK et al (2009) Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ. Gene Ther Mol Biol 13:20–25
Sato M, Tai T, Nunoura Y et al (2002) Dehydrotrametenolic acid induces preadipocyte differentiation and sensitizes animal models of noninsulin-dependent diabetes mellitus to insulin. Biol Pharm Bull 25:81–86
Li T-H, Hou C-C, Chang CL-T, Yang W-C (2011) Anti-hyperglycemic properties of crude extract and triterpenes from Poria cocos. Evid Based Complement Alternat Med 2011:128402. doi:10.1155/2011/128402
Guasch L, Sala E, Mulero M et al (2013) Identification of PPARgamma partial agonists of natural origin (II): in silico prediction in natural extracts with known antidiabetic activity. PLoS One 8:e55889. doi:10.1371/journal.pone.0055889
Mueller M, Lukas B, Novak J et al (2008) Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J Agric Food Chem 56:11621–11630. doi:10.1021/jf802298w
Fiévet C, Fruchart J-C, Staels B (2006) PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6:606–614. doi:10.1016/j.coph.2006.06.009
Lin H-R (2012) Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett 22:2954–2958. doi:10.1016/j.bmcl.2012.02.043
Shen P, Liu MH, Ng TY et al (2006) Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. J Nutr 136:899–905
Agget P, Alexander J, Alles M et al (1999) Scientific concepts of functional foods in Europe. Consensus document. Br J Nutr 81(Suppl 1):S1–27
Penumetcha M, Santanam N (2012) Nutraceuticals as ligands of PPARγ. PPAR Res 2012:858352. doi:10.1155/2012/858352
Song CM, Lim SJ, Tong JC (2009) Recent advances in computer-aided drug design. Brief Bioinform 10:579–591. doi:10.1093/bib/bbp023
Di L, Kerns EH, Carter GT (2009) Drug-like property concepts in pharmaceutical design. Curr Pharm Des 15:2184–2194
Peach ML, Zakharov AV, Liu R et al (2012) Computational tools and resources for metabolism-related property predictions. 1. Overview of publicly available (free and commercial) databases and software. Future Med Chem 4:1907–1932. doi:10.4155/fmc.12.150
Wermuth CG, Ganellin CR, Lindberg P, Mitscher LA (1998) Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998). Pure Appl Chem 70:1129–1143. doi:10.1351/pac199870051129
Caporuscio F, Tafi A (2011) Pharmacophore modelling: a forty year old approach and its modern synergies. Curr Med Chem 18:2543–2553
Dixon SL, Smondyrev AM, Knoll EH et al (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des 20:647–671. doi:10.1007/s10822-006-9087-6
Wolber G, Langer T (2005) LigandScout: 3-D Pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 45:160–169. doi:10.1021/ci049885e
Sousa SF, Ribeiro AJM, Coimbra JTS et al (2013) Protein-ligand docking in the new millennium—a retrospective of 10 years in the field. Curr Med Chem 20:2296–2314. doi:10.2174/0929867311320180002
Sousa SF, Fernandes PA, Ramos MJ (2006) Protein–ligand docking: current status and future challenges. Proteins Struct Funct Bioinforma 65:15–26. doi:10.1002/prot.21082
Kitchen DB, Stahura FL, Bajorath J (2004) Computational techniques for diversity analysis and compound classification. Mini Rev Med Chem 4:1029–1039
Maggiora GM, Vogt M, Stumpfe D, Bajorath J (2013) Molecular similarity in medicinal chemistry. J Med Chem. doi:10.1021/jm401411z
Verma J, Khedkar VM, Coutinho EC (2010) 3D-QSAR in drug design—a review. Curr Top Med Chem 10:95–115
Fischer PM (2008) Computational chemistry approaches to drug discovery in signal transduction. Biotechnol J 3:452–470. doi:10.1002/biot.200700259
Kar S, Roy K (2013) How far can virtual screening take us in drug discovery? Expert Opin Drug Discov 8:245–261. doi:10.1517/17460441.2013.761204
Hawkins PCD, Warren GL, Skillman AG, Nicholls A (2008) How to do an evaluation: pitfalls and traps. J Comput Aided Mol Des 22:179–190. doi:10.1007/s10822-007-9166-3
Cereto-Massagué A, Ojeda MJ, Joosten RP et al (2013) The good, the bad and the dubious: VHELIBS, a validation helper for ligands and binding sites. J Cheminform 5:36. doi:10.1186/1758-2946-5-36
Kirchmair J, Markt P, Distinto S et al (2008) Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments, and decoy selection–what can we learn from earlier mistakes? J Comput Aided Mol Des 22:213–228. doi:10.1007/s10822-007-9163-6
Cereto-Massagué A, Guasch L, Valls C et al (2012) DecoyFinder: an easy-to-use python GUI application for building target-specific decoy sets. Bioinformatics 28:1661–1662. doi:10.1093/bioinformatics/bts249
Truchon J-F, Bayly CI (2007) Evaluating virtual screening methods: good and bad metrics for the “Early Recognition” problem. J Chem Inf Model 47:488–508. doi:10.1021/ci600426e
Tanrikulu Y, Rau O, Schwarz O et al (2009) Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists. Chembiochem 10:75–78. doi:10.1002/cbic.200800520
Rupp M, Schroeter T, Steri R et al (2010) From machine learning to natural product derivatives that selectively activate transcription factor {PPAR} gamma. ChemMedChem 5:191–194. doi:10.1002/cmdc.200900469
Fakhrudin N, Ladurner A, Atanasov AG et al (2010) Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma. Mol Pharmacol 77:559–566. doi:10.1124/mol.109.062141
Petersen RK, Christensen KB, Assimopoulou AN et al (2011) Pharmacophore-driven identification of PPARγ agonists from natural sources. J Comput Aided Mol Des 25:107–116. doi:10.1007/s10822-010-9398-5
Irwin JJ, Sterling T, Mysinger MM et al (2012) ZINC: a free tool to discover chemistry for biology. J Chem Inf Model 52:1757–1768. doi:10.1021/ci3001277
Li Y, Li L, Chen J et al (2009) 7-Chloroarctinone-b as a new selective PPARgamma antagonist potently blocks adipocyte differentiation. Acta Pharmacol Sin 30:1351–1358. doi:10.1038/aps.2009.113
Hwang BY, Lee J-H, Nam JB et al (2002) Two new furanoditerpenes from Saururus chinenesis and their effects on the activation of peroxisome proliferator-activated receptor gamma. J Nat Prod 65:616–617
Choi S-S, Cha B-Y, Iida K et al (2011) Artepillin C, as a PPARγ ligand, enhances adipocyte differentiation and glucose uptake in 3T3-L1 cells. Biochem Pharmacol 81:925–933. doi:10.1016/j.bcp.2011.01.002
Malapaka RR V, Khoo S, Zhang J et al (2012) Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J Biol Chem 287:183–195. doi:10.1074/jbc.M111.294785
Atanasov AG, Blunder M, Fakhrudin N et al (2013) Polyacetylenes from Notopterygium incisum—new selective partial agonists of peroxisome proliferator-activated receptor-gamma. PLoS One 8:e61755. doi:10.1371/journal.pone.0061755
Pferschy-Wenzig E-M, Atanasov AG, Malainer C et al (2014) Identification of isosilybin a from milk thistle seeds as an agonist of peroxisome proliferator-activated receptor gamma. J Nat Prod 77:842–847. doi:10.1021/np400943b
Dang Z-C, Audinot V, Papapoulos SE et al (2003) Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 278:962–967. doi:10.1074/jbc.M209483200
Acknowledgments
This manuscript was edited for English-language fluency by American Journal Experts. This study was supported by grant AGL2011-25831/ALI from the Spanish Government and ACC1Ó program [TECCT11-1-0012] as well as grant XRQTC from ‘Generalitat de Catalunya’.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Garcia-Vallve, S., Guasch, L., Mulero, M. (2014). Discovery of Natural Products that Modulate the Activity of PPARgamma: A Source for New Antidiabetics. In: Martinez-Mayorga, K., Medina-Franco, J. (eds) Foodinformatics. Springer, Cham. https://doi.org/10.1007/978-3-319-10226-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-10226-9_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10225-2
Online ISBN: 978-3-319-10226-9
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)